SYNERGIA MEDICAL
RECOGNISED BY EIC ACCELERATOR FOR THE EXCELLENT
POTENTIAL OF ITS EPILEPSY TREATMENT SOLUTION
Immediate €2.5m grant and future investment of up to €7.5m
Synergia Medical, a preclinical medical device company that has developed NAO.VNS (Vagus Nerve Stimulation), the first non-metal optoelectronic neurostimulator for the treatment of drug-resistant epilepsy, today announced that it has been awarded a €2.5 million grant from the EIC Accelerator
program with the potential for an equity investment from the EU in the future Series C fund raising of a further €7.5 million.
« We are very honoured to have met the stringent selection criteria against tough competition and for our team to be recognized for our ground breaking work. The support of the EIC jury gives a further seal of approval to our belief that NAO.VNS has all the potential to be the next-generation implantable vagus nerve neurostimulator. We look forward to our upcoming Human trials and to bring this personalized solution to the many Drug Resistant Epilepsy (DRE) patients as soon as feasible.” declared Attila Borbath, CEO & Co-founder of Synergia Medical
More info : PR Synergia EIC GRANT AWARD OCT 2022 VDEF_.
